NCT07818239

Brief Summary

In a typical clinical setting, patient eating habits are not controlled when performing optical coherence tomography (OCT) imaging for retinal diagnostics. Nevertheless, the timing of the patient's most recent meal has the potential to impact OCT metrics particularly for those involving blood vessels, such as vascular density. Studies have shown that eating a high fat meal can increase blood fat levels in the hours following the meal. In particular, chylomicrons, the fat particles that will most likely affect the OCT signal, peak in concentration about 2-3 hours after eating. Preclinical animal studies have shown that intravascular injections of fat emulsions in rodent models can cause an increase in OCT signal and make blood vessels more visible. This study investigates the impact of a single high fat meal on OCT and OCT angiography (OCTA) measurements of retinal vessels and whether these effects differ from the effects of a single low-fat, high carbohydrate meal.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
11mo left

Started Sep 2026

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Sep 2026Sep 2027

Study Start

First participant enrolled

September 1, 2026

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 3, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

September 14, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

September 14, 2026

Status Verified

September 1, 2026

Enrollment Period

6 months

First QC Date

September 3, 2026

Last Update Submit

September 7, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Retinal vessel area density (OCTA)

    Retinal vessel area density measured by OCTA

    On both study days, from the start of the meal consumption every 30 min up to 5 hours after meal consumption; BL, 30min, 60min, 90min, 120min, 150min, 180min, 210min, 240min, 270min, 300min

Study Arms (2)

High carbohydrate

ACTIVE COMPARATOR
Other: Consumption of a high fat mealOther: Consumption of a high carbohydrate meal

High fat

ACTIVE COMPARATOR
Other: Consumption of a high fat mealOther: Consumption of a high carbohydrate meal

Interventions

Consumption of a high fat meal: Volume 500ml, Lipid 80 % of calories

High carbohydrateHigh fat

Consumption of a high carbohydrate meal: Volume 500ml, Carbohydrate 80% of calories

High carbohydrateHigh fat

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women aged over 18 years
  • Signed informed consent
  • Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
  • Normal ophthalmic findings

You may not qualify if:

  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day
  • Presence or history of a severe medical condition as judged by the clinical investigator
  • Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study (except hormonal contraceptives)
  • Untreated arterial hypertension (defined as either systolic blood pressure \>150 mmHg or diastolic blood pressure \>95 mmHg)
  • Blood donation during the previous three weeks
  • Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator
  • Pregnancy, planned pregnancy or lactating
  • Lactose intolerance or other relevant food allergy or sensitivity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Clinical Pharmacology, Medical University of Vienna

Vienna, Austria

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Crossover study design, two separate Arms
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc-Prof. Priv.-Doz. Dr.med.univ.; PhD

Study Record Dates

First Submitted

September 3, 2026

First Posted

September 14, 2026

Study Start

September 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

September 14, 2026

Record last verified: 2026-09

Locations